Author of

• 11001

  +

  P1.24 - Poster Session 1 - Clinical Care (ID 146)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Supportive Care
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/28/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 11017

    +

    P1.24-016 - Single agent oral etoposide for elderly and infirm advanced non small cell lung cancer : A reasonable therapeutic option (ID 1317)

    09:30 - 09:30  |  Author(s): K. Kosanam Subramaniam
    • Abstract

    Background
    Background: The use of chemotherapy has been shown to increase the effectiveness of best supportive care (BSC) in elderly patients with non-small cell lung cancer (NSCLC). The use of Intravenous chemotherapy ( IV ) has many times been difficult in elderly patients or patients with poor performance status owing to fear of toxicity.We studied the effectiveness of a non toxic regimen with single agent oral chemotherapy with etoposide plus best supportive care versus best supportive care alone in subjects with advanced non small cell lung cancer unfit for IV chemotherapy

    Methods
    Eighty five cases of advanced non small cell lung cancer and ECOG performance status of 2 to 3 , unfit for IV chemotherapy as per treating physician's discretion were included in the study. Forty three patients received chemotherapy with Tablet Etoposide 50 mg once daily for 14 days along with best supportive care ( BSC )every 21 days for a maximum of 8 cycles in responding patients. Regimen was re challenged on progression. The remaining received BSC only.

    Results
    We measured at least 1 of the following outcomes: Overall survival ( OS ) or treatment-related mortality. Overall, patients that received chemotherapy plus BSC had significant longer OS than those that received BSC alone (HR 0.75; 95%CI, 0.68–0.82; P,0.001). Additionally, chemotherapy plus BSC as compared to BSC alone resulted in a 24% RR reduction (95%CI: 10–38; P = 0.001) in 6-month mortality, 10% RR reduction (95%CI: 8–15; P,0.001) in 12-month mortality and 6% RR reduction (95%CI: 2–9; P = 0.02) in 2-year mortality. Toxicity was not significantly greater in patients who received chemotherapy plus BSC.

    Conclusion
    Chemotherapy with single agent oral etoposide plus BSC is a non toxic therapeutic option in infirm and elderly NSCLC patients unfit to receive intravenous chemotherapy.